Clinical characteristics and disease course before and after SARS-CoV-2 infection in a large cohort of systemic sclerosis patients.

Autor:	Güler AA; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkiye., Özçimen B; Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkiye., Aydoğdu MS; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fırat University, Elazığ, Turkiye., Sari A; Department of Rheumatology, Etlik City Hospital, Ankara, Turkiye., Numune A; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, İstanbul University, İstanbul, Turkiye., Ersan NT; Department of Internal Medicine, Gazi University Hospital, Ankara, Turkiye., Çolak S; Department of Rheumatology, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Turkiye., Karadeniz H; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkiye., Vasi İ; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkiye., Küçük H; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkiye., Yalçinkaya Y; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, İstanbul University, İstanbul, Turkiye., Erden A; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkiye., Kayaalp M; Department of Internal Medicine, Yıldırım Beyazıt University, Ankara, Turkiye., Öztürk MA; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkiye., Göker B; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkiye., Omma A; Department of Rheumatology, Ankara City Hospital, Health Sciences University, Ankara, Turkiye., Yilmaz S; Department of Rheumatology, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Turkiye., Koca SS; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fırat University, Elazığ, Turkiye., Inanç M; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, İstanbul University, İstanbul, Turkiye., Akdoğan A; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkiye., Tufan A; Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkiye.; Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, Maryland, USA.
Jazyk:	angličtina
Zdroj:	Turkish journal of medical sciences [Turk J Med Sci] 2023 Dec 21; Vol. 54 (1), pp. 76-85. Date of Electronic Publication: 2023 Dec 21 (Print Publication: 2024).
DOI:	10.55730/1300-0144.5768
Abstrakt:	Background/aim: The objective of this study is to evaluate the clinical presentations and adverse outcomes of Coronavirus Disease 2019 (COVID-19) in patients with systemic sclerosis (SSc) and assess the impact of SSc features on the clinical course of COVID-19. Materials and Methods: In this multicenter, retrospective study, SSc patients with COVID-19 were included. Clinical features of SSc, along with detailed COVID-19 data, were extracted from medical records and patient interviews. Results: The study included 112 patients (mean age 51.4 ± 12.8 years; 90.2% female). SSc-associated interstitial lung disease (ILD) was evident in 57.1% of the patients. The findings revealed hospitalization in 25.5%, respiratory support in 16.3%, intensive care unit admission in 3.6%, and a mortality rate of 2.7% among SSc patients with COVID-19. Risk factors for respiratory failure, identified through univariate analysis, included ILD (OR: 7.49, 95% CI: 1.63-34.46), ≥1 comorbidity (OR: 4.55, 95% CI: 1.39-14.88), a higher physician global assessment score at the last outpatient visit (OR 2.73, 95% CI: 1.22-6.10), and the use of mycophenolate at the time of infection (OR: 5.16, 95 %CI: 1.79-14.99). Notably, ≥1 comorbidity emerged as the sole significant predictor of the need for respiratory support in COVID-19 (OR: 5.78, 95% CI: 1.14-29.23). In the early post-COVID-19 period, 17% of patients reported the progression of the Raynaud phenomenon, and 10.6% developed new digital ulcers. Furthermore, progression or new onset of dyspnea and cough were detected in 28.3% and 11.4% of patients, respectively. Conclusion: This study suggests a potential association between adverse outcomes of COVID-19 and SSc-related ILD, severe disease activity, and the use of mycophenolate. Additionally, it highlights that having comorbidities is an independent risk factor for the need for respiratory support in COVID-19 cases. (© TÜBİTAK.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF